DermaGold is an extracorporeal shock wave therapy (ESWT) device that produces a biological response that encourages angiogenesis and promotes wound healing.
• Non-invasive and non-surgical treatment
• Supports faster healing time
• Convenient for patient and provider
• Biological response includes growth-factor upregulation, inflammatory modulation and improved micro-vascularization and micro-circulation
DermaGold is indicated for use on diabetic foot ulcers and second-degree burns.
Do not use on on the lung and head area, on patients with malignancies, coagulation disorders, children, pregnant patients, wounds greater than 16sq cm, on patients with a BMI greater than or equal to 40 or patients on dialysis.
Reddening, bruising, tingling, numbness, brief increase of pain is possible, as well as infection of the wound or beyond the wound.
Store at room temperature.
|Contact manufacturer for more details||●|
|Educational Material Available||●|
|Free Samples/Trials Available||●|
|Published Clinical Article Available||●|
SoftWave Tissue Regeneration Technologies is a bio-medical technology company that manufactures DermaGold, an FDA-cleared device for the treatment of diabetic foot ulcers and second-degree burn wounds.